Education
About Us
Working with TipRanks
Follow Us
Emmaus Life Sciences Inc (EMMA)
OTHER OTC:EMMA
EMMA Stock Chart & Stats
$0.01
<$0.01(41.41%)
At close: 4:00 PM EST
$0.01
<$0.01(41.41%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.03
Previous CloseN/A
Volume11.42K
Average Volume (3M)112.45K
Market Cap
$894.12K
Enterprise Value$32.32M
Total Cash (Recent Filing)$293.00K
Total Debt (Recent Filing)$31.69M
Price to Earnings (P/E)―
Beta60.75
Next Earnings
Mar 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding63,865,570
10 Day Avg. Volume152,781
30 Day Avg. Volume112,453
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.03
P/FCF Ratio-0.23
Enterprise Value/Market Cap36.15
Enterprise Value/Revenue2.72
Enterprise Value/Gross Profit2.95
Enterprise Value/Ebitda-28.91
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginA high gross margin indicates efficient cost management, allowing the company to retain a significant portion of revenue as profit, which is crucial for sustaining operations and funding future growth initiatives.
Exclusive Distribution AgreementThe agreement enhances market reach and could increase revenue through upfront payments and royalties, leveraging NeoImmuneTech's infrastructure to expand Endari's presence in North America.
Strategic Focus On Rare DiseasesFocusing on rare diseases, where competition is limited and demand is high, positions Emmaus to capture niche markets with significant unmet needs, supporting long-term revenue potential.
Bears Say
Declining RevenueA significant revenue decline indicates challenges in maintaining market share or product demand, which can hinder growth and strain financial resources needed for future investments.
Negative Cash FlowPersistent negative cash flow suggests ongoing cash burn, limiting the company's ability to invest in growth opportunities and increasing reliance on external financing, which can be costly and dilutive.
High Leverage And Negative EquityHigh leverage and negative equity pose solvency risks, reducing financial flexibility and increasing vulnerability to economic downturns, potentially impacting long-term viability.
Emmaus Life Sciences News
EMMA FAQ
What was Emmaus Life Sciences Inc’s price range in the past 12 months?
Emmaus Life Sciences Inc lowest stock price was <$0.01 and its highest was $0.03 in the past 12 months.
What is Emmaus Life Sciences Inc’s market cap?
Emmaus Life Sciences Inc’s market cap is $894.12K.
When is Emmaus Life Sciences Inc’s upcoming earnings report date?
Emmaus Life Sciences Inc’s upcoming earnings report date is Mar 27, 2026 which is in 23 days.
How were Emmaus Life Sciences Inc’s earnings last quarter?
Emmaus Life Sciences Inc released its earnings results on Nov 14, 2025. The company reported -$0.032 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.032.
Is Emmaus Life Sciences Inc overvalued?
According to Wall Street analysts Emmaus Life Sciences Inc’s price is currently Overvalued.
Does Emmaus Life Sciences Inc pay dividends?
Emmaus Life Sciences Inc does not currently pay dividends.
What is Emmaus Life Sciences Inc’s EPS estimate?
Emmaus Life Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Emmaus Life Sciences Inc have?
Emmaus Life Sciences Inc has 63,865,570 shares outstanding.
What happened to Emmaus Life Sciences Inc’s price movement after its last earnings report?
Emmaus Life Sciences Inc reported an EPS of -$0.032 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -16.667%.
Which hedge fund is a major shareholder of Emmaus Life Sciences Inc?
Currently, no hedge funds are holding shares in EMMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Emmaus Life Sciences Inc
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Technical Analysis
Scinai Immunotherapeutics
―
Aditxt
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
CDT Equity
―
Ownership Overview
16.80%
Insiders
0.09% Other Institutional Investors
83.11% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---